Citadel Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-175,052
| Closed | -$90.6K | – | 14377 |
|
|
2024
Q4 | $94.3K | Buy |
+175,052
| New | +$128K | ﹤0.01% | 11563 |
|
|
2024
Q3 | – | Sell |
-142,891
| Closed | -$162K | – | 14130 |
|
|
2024
Q2 | $139K | Sell |
142,891
-100,800
| -41% | -$111K | ﹤0.01% | 10452 |
|
|
2024
Q1 | $385K | Sell |
243,691
-3,155,823
| -93% | -$3.81M | ﹤0.01% | 8933 |
|
|
2023
Q4 | $2.7M | Sell |
3,399,514
-150,045
| -4% | -$84.6K | ﹤0.01% | 4839 |
|
|
2023
Q3 | $2.77M | Buy |
3,549,559
+179,476
| +5% | +$151K | ﹤0.01% | 4626 |
|
|
2023
Q2 | $3.12M | Buy |
3,370,083
+2,243,065
| +199% | +$2.67M | ﹤0.01% | 4399 |
|
|
2023
Q1 | $1.23M | Buy |
1,127,018
+884,381
| +364% | +$1.37M | ﹤0.01% | 6335 |
|
|
2022
Q4 | $354K | Sell |
242,637
-1,295,049
| -84% | -$2.1M | ﹤0.01% | 8959 |
|
|
2022
Q3 | $1.65M | Buy |
1,537,686
+31,531
| +2% | +$57.9K | ﹤0.01% | 5952 |
|
|
2022
Q2 | $2.56M | Sell |
1,506,155
-242,336
| -14% | -$416K | ﹤0.01% | 5051 |
|
|
2022
Q1 | $3.6M | Buy |
1,748,491
+221,412
| +14% | +$598K | ﹤0.01% | 4819 |
|
|
2021
Q4 | $5.73M | Sell |
1,527,079
-1,164,049
| -43% | -$5.3M | ﹤0.01% | 4064 |
|
|
2021
Q3 | $13.9M | Buy |
2,691,128
+2,540,526
| +1,687% | +$11.4M | ﹤0.01% | 2537 |
|
|
2021
Q2 | $642K | Sell |
150,602
-2,324,950
| -94% | -$11.3M | ﹤0.01% | 9448 |
|
|
2021
Q1 | $13.1M | Buy |
2,475,552
+544,888
| +28% | +$3.12M | ﹤0.01% | 2568 |
|
|
2020
Q4 | $10.4M | Sell |
1,930,664
-2,960,382
| -61% | -$16.1M | ﹤0.01% | 2594 |
|
|
2020
Q3 | $39M | Buy |
4,891,046
+1,701,878
| +53% | +$14.9M | 0.01% | 1024 |
|
|
2020
Q2 | $31.9M | Buy |
3,189,168
+1,135,963
| +55% | +$7.13M | 0.01% | 1115 |
|
|
2020
Q1 | $5.58M | Buy |
+2,053,205
| New | +$6.81M | ﹤0.01% | 2567 |
|
|
2019
Q4 | – | Sell |
-18,962
| Closed | -$29K | – | 9032 |
|
|
2019
Q3 | $29K | Sell |
18,962
-59,793
| -76% | -$140K | ﹤0.01% | 8852 |
|
|
2019
Q2 | $317K | Buy |
78,755
+6,089
| +8% | +$24.8K | ﹤0.01% | 7498 |
|
|
2019
Q1 | $312K | Buy |
72,666
+45,878
| +171% | +$214K | ﹤0.01% | 7560 |
|
|
2018
Q4 | $154K | Sell |
26,788
-217,501
| -89% | -$1.6M | ﹤0.01% | 8042 |
|
|
2018
Q3 | $3.31M | Buy |
244,289
+131,009
| +116% | +$1.37M | ﹤0.01% | 3574 |
|
|
2018
Q2 | $1.34M | Buy |
+113,280
| New | +$1.41M | ﹤0.01% | 4721 |
|
|
2017
Q4 | – | Sell |
-83,423
| Closed | -$683K | – | 7914 |
|
|
2017
Q3 | $683K | Buy |
83,423
+63,664
| +322% | +$398K | ﹤0.01% | 4877 |
|
|
2017
Q2 | $89K | Buy |
+19,759
| New | +$103K | ﹤0.01% | 6948 |
|
|
2015
Q4 | – | Sell |
-655,279
| Closed | -$7.84M | – | 8665 |
|
|
2015
Q3 | $7.84M | Buy |
655,279
+478,519
| +271% | +$6.76M | 0.01% | 1530 |
|
|
2015
Q2 | $3.24M | Buy |
+176,760
| New | +$3.03M | ﹤0.01% | 2507 |
|
Other funds holding ADAP
JAIC
EF
RG
XT
Citadel Advisors's ADAP Position: Q1 2025 in Review
Citadel Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q1 2025, closing a stake of 175,052 shares — an estimated $90.6K sold.
Citadel Advisors first reported a position in ADAP in Q2 2015 and held it in 29 quarters. The position peaked at $39M in Q3 2020. 67 funds tracked by Wall St. Rank hold ADAP as of Q1 2025.
- Citadel Advisors reported no remaining Adaptimmune Therapeutics position as of Q1 2025 after selling out during the quarter.
- Citadel Advisors sold 175,052 Adaptimmune Therapeutics shares in Q1 2025, an estimated $90.6K.
- Citadel Advisors first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 29 quarters.
- Citadel Advisors's Adaptimmune Therapeutics position peaked at $39M in Q3 2020.
- 67 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.